The U.S. Food and Drug Administration has licensed Ezplaz Freeze Dried Plasma, marking the first time a freeze-dried plasma product has been approved for use in the United States. Manufactured by Vascular Solutions, LLC, a subsidiary of Teleflex, the product is intended for adult patients who require plasma when other conventional plasma products are unavailable.
FDA Approves First US Freeze-Dried Plasma Product
The authorization addresses significant logistical hurdles associated with traditional blood products. Conventional plasma must be stored frozen and thawed prior to transfusion, requirements that restrict its availability in ambulances, disaster zones, rural areas, and combat environments far from hospital infrastructure. In contrast, the newly approved product can be stored at room temperature, remains stable through temperature fluctuations, and can be rapidly prepared for use.
Logistical Breakthrough and Kit Components
Derived from a single unit of fresh frozen plasma, Ezplaz is supplied in a self-contained package designed for rapid deployment. According to regulatory details, each kit includes:
- One unit of freeze-dried plasma sealed in an outer foil pouch
- One 250-milliliter bag of sterile water for injection
- One sterile fluid transfer set
- One sterile blood transfusion set
Unlike existing emergency use authorization products that rely on glass bottles, Ezplaz is packaged in a flexible plastic bag to reduce the risk of breakage during transport Sciencealert. The product features a 12-month shelf life when stored at temperatures between 2 and 25 degrees Celsius (36 to 77 degrees Fahrenheit) and can be fully reconstituted in one to 2.5 minutes by adding the provided sterile water.
Indications and Clinical Administration
The FDA approved the product in blood Group AB and Group A with low-titer anti-B antibodies. These specific types were selected to mitigate the risk of adverse transfusion reactions when medics must administer plasma in emergencies before a patient’s exact blood type is determined.
The license covers specific adult patient populations and clinical scenarios, including:
- Patients experiencing bleeding who require the replacement of multiple plasma coagulation factors
- Individuals undergoing massive transfusions with clinically significant coagulation deficiencies
- Patients taking warfarin who are actively bleeding or require an invasive procedure before vitamin K can reverse the drug’s effects
Karim Mikhail, acting director of the Center for Biologics Evaluation and Research (CBER), noted that the milestone action addresses an important unmet medical need for military personnel and others situated far from traditional hospital infrastructure.
Safety Profile and Regulatory Background
The approval was supported by data from a Phase 1 safety and tolerability dose-escalation study involving 24 healthy adults. Findings indicated that the product was generally well tolerated across escalating doses from one unit to three units, with no clinically significant safety signals or laboratory changes observed.
However, federal regulators and health officials emphasize that the product is not risk-free. Like other plasma transfusions, Ezplaz carries potential risks including allergic reactions, transfusion-related lung injury, circulatory overload, and reactions caused by incompatible blood types. The overall safety profile is consistent with other plasma products, and the FDA concluded that its benefits outweigh its risks for the limited circumstances covered by the license.
The development path was shaped by Public Law 115-92, enacted in December 2017, which authorized a collaboration between the Department of Defense and the FDA to expedite the review of products for serious conditions facing American military personnel.
